Business Context and Reporting Period
Company: Alterity Therapeutics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2020
Date Filed: September 21, 2020
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of corporate governance changes rather than a financial statement.
Material Changes
The primary material change disclosed in this filing is the submission of Change of Director's Interest Notices (Item 99.1). No financial material changes were reported in this specific document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to incorporate Change of Director's Interest Notices by reference into existing Registration Statements (Form S-8 and Form F-3).
Key Facts for Investor Verification
- Verify the specific details of the Change of Director's Interest Notices referenced in Item 99.1, as the full text of those notices is not included in this summary.
- Confirm the impact of these director interest changes on the company's governance structure.
- Note that this filing incorporates information into Registration Statements File Nos. 333-228671, 333-220886, and 333-231417.